Legend Biotech awards director 20,986 share units
The award vests in stages starting December 20, 2027, and continued service is required on each vesting date.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Legend Biotech Corp (LEGN) director Li Mao received an award of 20,986 restricted share units on September 24, 2026. Each RSU represents a contingent right to receive one ordinary share upon settlement. One-third of the RSUs vest on December 20, 2027, with the remainder vesting in 12 equal quarterly installments beginning March 20, 2028, subject to continued service on each vesting date. The reported direct position following the award was 65,316 ordinary shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Ordinary Shares F1, F2 | 20,986 | $0.00 | $0.00 |
Footnotes (2)
- F1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
- F2. Represents restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 1/3 of the RSUs will vest on December 20, 2027, with the remainder of the RSUs vesting in 12 equal quarterly installments beginning on March 20, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Key Terms
settlement financial
vesting financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many RSUs did Li Mao receive from Legend Biotech (LEGN)?
AI-generated analysis. How Rhea-AI works. Not financial advice.